Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies


Lead product candidate, ZB001, has first-in-class potential in China for Thyroid Eye Disease

Rapidly advancing seven pipeline programs, including three worldwide, with best-in-class potential in autoimmune and rare diseases

Expanding a proven leadership team of veteran life science industry executives

Company founded and initially funded by Tellus BioVentures and Fairmount

HONG KONG and BOSTON, March 23, 2021 (GLOBE NEWSWIRE) -- Zenas BioPharma (“Zenas”) launched today as a cross-border biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and throughout the world.

Zenas was founded and initially funded by Tellus BioVentures, LLC (“Tellus”) and Fairmount Funds Management LLC (“Fairmount”) and is additionally backed by a syndicate of leading global life science investment funds including Quan Capital, WuXi Biologics Healthcare Ventures and Wellington Management.

Lonnie Moulder, Managing Member of Tellus and Founder of Zenas, serves as Executive Chairman and Interim Chief Executive Officer. As a veteran life sciences founder and executive, he brings to Zenas a track record of success and the necessary skills to navigate the global biopharmaceutical landscape. Mr. Moulder has assembled an experienced leadership team with strong credentials in acquiring, developing and commercializing products across the globe.

“We are excited about the launch of Zenas BioPharma and its pipeline of differentiated product candidates. These potentially best-in-class products are intended to bring innovation to patients with underserved diagnoses while also maximizing value across the healthcare ecosystem,” said Mr. Moulder. “The expanding Zenas leadership team and our network of business partners will drive operational excellence to deliver potentially transformative therapies to improve the lives of people living with autoimmune and rare diseases.”

“We are thrilled to invest in and support this new venture lead by a proven and experienced team,” added Marietta Wu, MD, Ph.D., MBA, Managing Director at Quan Capital and Zenas Board Member. “Immunology is an area of transformative innovation poised to solve great unmet medical needs. We are confident that by leveraging cross border research and development capabilities and resources, Zenas will rapidly advance its current portfolio and establish its global leadership with an expanded pipeline coupled with a strong footprint in China.”

Rapidly Advancing Pipeline

Zenas debuts with a deep pipeline of seven innovative immune-based therapeutics that will continue to expand through a successful business development strategy. Zenas owns worldwide rights to three of the seven pipeline programs, which uniquely positions the Company to be global in scope.

Zenas innovation is defined by the selection of product candidates that are designed with best-in-class potential and then advanced utilizing differentiated development and commercial strategies to address patient needs AND the value requirements of the dynamic healthcare environment. Zenas innovation further includes acquiring or discovering first-in-class product candidates based upon new knowledge in the evolving field of immunology.

ZB001 and ZB011

Zenas is developing its lead product candidate ZB001, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (mAb), for the potential treatment of patients in China with thyroid eye disease (TED). TED is a debilitating condition that significantly impacts quality of life and can cause proptosis (“bulging eyes”), double vision and vision loss. ZB001, a potential first-in-class product in China, was exclusively in-licensed from Viridian Therapeutics, Inc. (“Viridian”) (NASDAQ: VRDN).

More than 100 oncology patients have previously been treated with the antibody in US and EU studies, under the name AVE-1642, enabling understanding of its pharmacokinetic and pharmacodynamic profile, as well as its safety and tolerability. Viridian maintains all rights outside of China and is developing the IGF1R mAb under the name VRDN-001. This program is advancing rapidly with an expected Investigational New Drug (“IND”) application filing by Viridian in late 2021, followed by a Zenas filing in China. Data from the first clinical trial involving patients is expected to be available in 2022.

In parallel with ZB001 development, Viridian and Zenas initiated the ZB011 program, which seeks to improve IGF1R-targeted antibodies to further enhance dosing and convenience.

ZB002, ZB003 and ZB004

The Zenas pipeline also includes three potentially best-in-class mAbs (ZB002, ZB003, ZB004) exclusively in-licensed worldwide from Xencor, Inc. (NASDAQ: XNCR). These three mAbs were engineered with XmAb™ technology for improved potency, half-life, and stability and are undergoing IND-enabling studies to support clinical development for both new and established autoimmune disease indications.

ZB005 and ZB006

Zenas additionally entered a collaboration with Dianthus Therapeutics, Inc. (“Dianthus”) that provides China rights for two mAb programs, ZB005 and ZB006. Dianthus is a privately held biotechnology company focused on the discovery and development of monoclonal antibody therapeutics that modulate the immune complement system for the treatment of autoimmune diseases. IND-enabling activities are underway for ZB005, the first of the two programs.

About Zenas BioPharma

Zenas BioPharma is a cross-border (China-USA based) biopharmaceutical company committed to becoming a global leader in the development and delivery of immune-based therapies for patients in China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit and follow us on Twitter at @ZenasBioPharma and LinkedIn.


Investor Contact:

Zenas BioPharma

Media Contact:

Lauren Bartlett
Zenas BioPharma

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)12.4.2021 15:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 12 April 2021 at 4:30 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the number of Sampo A shares (ISIN: FI009003305) owned directly or indirectly by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 9 April 2021 below five (5) per cent Sampo plc's total stock. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B) Resulting situation on the date on which thres

Vertex Welcomes Dynamic Leader Yvette C. Burton, Ph.D. As Chief People Innovation Officer12.4.2021 14:47:00 CEST | Press release

Executive Leadership to Advance Company’s Global Workforce Strategy KING OF PRUSSIA, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, is honored to welcome Yvette C. Burton, Ph.D. as its first Chief People Innovation Officer, effective immediately. Dr. Burton is responsible for shaping the company’s global strategic workforce planning efforts and leading organizational programs to advance inclusion and diversity. Burton comes to Vertex from Columbia University, where she was the academic director of the school’s Human Capital Management Program. She will draw on her executive expertise, including over 20 years in high-impact human capital strategies for the media, consumer, industrial product, and defense industries, to lead and engage employees worldwide. Burton was also named to Crain's New York inaugural list of Notable LGBTQ Leaders and Executives in 2020. “We welcome Yvette and her rare c

Industry Leading SAFR Facial Recognition for Live Video Integrated with Geutebrück VMS12.4.2021 13:00:00 CEST | Press release

Featuring real-time, automated, low-bias identification of opt-in staff and persons of interest SEATTLE, April 12, 2021 (GLOBE NEWSWIRE) -- SAFR from RealNetworks, Inc. (NASDAQ: RNWK) today announced that its SAFR facial recognition system for live video is now integrated with the Geutebrück G-Core VMS (Video Management System). SAFR for Geutebrück is an AI layer that runs on top of the G-Core VMS which provides advanced video analytics that save time and increase efficiency of surveillance operations. The best-in-class integration features live video overlays that display event details, streamlined enrollment of individuals appearing on the Geutebrück VMS directly into the SAFR identity database, and custom alarms and notifications that notify security personnel of SAFR events directly within the VMS. With so many cameras deployed, it’s impossible for security staff to monitor them effectively. SAFR matches faces appearing in live video feeds against watchlist images more effectively

Rockridge Stakes Additional Ground at the Knife Lake Copper Project, Saskatchewan12.4.2021 13:00:00 CEST | Press release

VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd. (TSX-V: ROCK) (OTCQB: RRRLF) (Frankfurt: RR0) (“Rockridge” or the “Company”) is pleased to announce that it has recently acquired additional mineral rights through staking at its Knife Lake Copper Project located in Saskatchewan, Canada (the “Knife Lake Project” or “Property”). The Knife Lake Project, now consisting of 81 dispositions totaling 55,471 hectares (137,069 acres), is an advanced-stage copper, silver, zinc and cobalt exploration property in Saskatchewan. With the recent staking, the Company has increased the project area by 70% from 32,663 hectares (80,712 acres). Knife Lake Claims Map: Based on encouraging observations made during the current drill program the newly acquired claims are considered to be highly prospective for VMS mineralization. The staking completed has added to the land package s

Signify share repurchase periodic update12.4.2021 13:00:00 CEST | Press release

Press Release April 12, 2021 Signify share repurchase periodic update Eindhoven, the Netherlands –Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 131,684 shares in the period April 6 to April 9, 2021. The shares were repurchased at an average price of EUR 44.36 per share and an aggregate amount of EUR 5.8 million. These repurchases were made as part of the company’s repurchase program, which was announced on February 25, 2021. Signify will use the shares to cover obligations arising from its long-term incentive performance share plan and other employee share plans. The total number of shares repurchased under this program to date is 968,157 shares for a total consideration of EUR 39.3 million. Details on the share buyback transactions can be found here. --- END --- For further information, please contact: Signify Investor Relations Thelke Gerdes Tel: +31 6 1801 7131 E-mail: Signify Corporate Communications Elco

Effnet licenses its ASN.1 5G Toolset and 5G gNB CU-UP software components12.4.2021 12:07:15 CEST | Press release

Luleå, 2021-04-12 -- Effnet, a subsidiary of Effnetplattformen AB and a leading provider of 5G protocol stack software for terminals and containerized 5G RAN software as well as Header Compression software, announces today that it has licensed its ASN.1 5G Toolset and 5G gNB CU-UP software components to a leading provider of open and cloud-native 4G and 5G RAN software solutions. Effnet ASN.1 5G Toolset uses modern C++. It is portable, robust and provides high performance. It currently has support for ASN.1 in 3GPP Release 15 (RRC, F1AP, E1AP, NGAP, XnAP and NRPPa) specifications and the O-RAN E2AP specification. For more information, visit Effnet 5G gNB CU-UP is a high quality and high-performance user plane software solution used in the Central Unit (CU) of a 5G gNB. Together with the Effnet DU software, this is a critical component to deliver data traffic (user plane) at exceedingly high rates. The software can deliver better radio resource effi

Statkraft bygger tre vindparker i Chile – verdens sørligste land12.4.2021 12:00:00 CEST | Pressemelding

(Santiago/Oslo, 12. april 2021) Statkraft skal for første gang bygge vindkraftverk i Chile, og øker dermed sin produksjonskapasitet for fornybar energi i det søramerikanske landet, hvor etterspørselen etter vann-, vind- og solkraft er stigende. Sammen med selskapets eksisterende vannkraftportefølje i Chile, vil Statkraft nå en produksjonskapasitet på 366 megawatt (MW) innen utgangen av 2023. Det 102 MW store vindprosjektet Torsa består av tre vindparker, med til sammen 19 turbiner fra den tyske produsenten Nordex. Samlet forventes vindparkene å produsere mer enn 300 GWh med fornybar energi i året – nok til å forsyne 100.000 gjennomsnittlige chilenske hjem. Prosjektet ligger i O’Higgins-regionen, 124 kilometer sør for hovedstaden Santiago. - Disse tre vindparkene øker ikke bare vår produksjonskapasitet i Chile; de utvider vår fornybarportefølje til å for første gang omfatte vindkraft. Framover planlegger vi også å inkludere solkraft i produksjonsmiksen vår, sier Statkrafts konserndirekt